Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer

Fig. 3

Clonogenic survivals. Clonogenic survival of CaSki and C-4I cells treated with γ-rays (a, n = 3), cisplatin (b, n = 3), or both (c, CaSki – n = 3 ; d, C-4I – n = 3). Experimental data points show means ± SEM, connected with dashed lines. Linear-quadratic curve fits (Eq. 1) to the data, obtained with the least-squares method, are shown with solid lines. e) Clonogenic survival fractions of CaSki (n = 3) and f) C-4I (n = 3) cells transfected with siRNAs; data were normalized to unirradiated controls for each respective treatment groups. g) Clonogenic survival fractions of C-4I (n = 2) and h) CaSki (n = 2) cells transfected with siRNAs; data were normalized to unirradiated controls for each respective treatment groups. NT: Non-treated; IR: 2 Gy γ-rays, CIS: IC30, CIS + IR: IC30 + 2Gy γ-rays. *P < 0.05 and **P < 0.01 refer to the unpaired t-test comparison between the silenced condition vs the silenced control, for each treatment. Representative Western Blots showing the efficiency of the silencing treatment 48 h since transfection

Back to article page